EXCLUSIVE: Ocean Biomedical Unveils Comprehensive Updates On Its Cancer, Malaria, Fibrosis Programs

Ocean Biomedical Inc OCEA shared an update on its broad range of programs in malaria, fibrosis, and multiple cancers.

Oncology Program:

• Ocean Biomedical is working on immunotherapies targeting brain and lung cancers.
• Early preclinical findings show a 60% tumor growth reduction in brain cancer and an 85%-95% tumor reduction in non-small cell lung cancer.
• Experimental results demonstrate that Ocean's antibodies inhibit pulmonary metastasis (tumor spread), including malignant melanoma.

Malaria Initiative:

• The company is advancing understanding and control of the mechanisms by which Ocean's PfGARP antigen induces malaria parasite death.
• Optimizing and developing an mRNA vaccine candidate based on discoveries of PfGARP, PfSEA, and another antigen that can simultaneously target the malaria parasite at different stages of the blood cycle, ideally for prevention in sub-Saharan Africa.

Fibrosis Research:

• Testing Ocean's anti-fibrotic treatment candidate, "OCF-203," has generated impressive fibrosis reductions in multiple models and reduced collagen accumulation by 85%-90%.
• Evaluating Ocean's anti-fibrotic treatment candidates' potential for use beyond IPF and HPS, with possible application in scleroderma, alcoholic liver disease, and non-alcoholic steatohepatitis.

Upcoming Event:

• On September 14, Ocean Biomedical's Research & Development Day: Live Q&A featuring its co-founders, Dr. Elias and Dr. Kurtis, shedding light on their work.

Price Action: OCEA shares are up 3.53% at $4.40 during the premarket session on the last check Thursday.